Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.83 |
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.67 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615877 | 1.00 | KCNH2 (0.83) | KCNH2MAP2K1MAP2K2BRAFMAPK1 | |
| SCHEMBL1615879 | 1.00 | KCNH2 (0.83) | KCNH2MAP2K1MAP2K2BRAFMAPK1 | |
| SCHEMBL18789312 | 0.92 | KCNH2 (0.87) | KCNH2MAP2K1MAP2K2BRAFMAPK1 | |
| SCHEMBL29683672 | 0.90 | KCNH2 (1.00) | KCNH2MAP2K1CYP2C9 | |
| SCHEMBL1614858 | 0.90 | KCNH2 (1.00) | KCNH2MAP2K1CYP2C9 | |
| SCHEMBL1616260 | 0.90 | KCNH2 (0.67) | KCNH2MAP2K1MAP2K2BRAFMAPK1 | |
| SCHEMBL1616256 | 0.90 | KCNH2 (0.67) | KCNH2MAP2K1MAP2K2BRAFMAPK1 | |
| SCHEMBL29683686 | 0.90 | KCNH2 (0.67) | KCNH2MAP2K1MAP2K2BRAFMAPK1 | |
| SCHEMBL19223717 | 0.90 | KCNH2 (0.70) | KCNH2MAP2K1MAP2K2 | |
| SCHEMBL29683598 | 0.88 | KCNH2 (0.78) | KCNH2MAP2K1MAP2K2BRAFMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390488-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20220105180-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390488-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | KCNH2 4598/4885MAP2K1 13/4885MAP2K2 17/4885 |
| US-20220105180-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | KCNH2 4598/4885MAP2K1 13/4885MAP2K2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.